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GFRAbstract Aim of the work: Obesity and the related metabolic syndrome cluster of cardiovascular
risk factors have been associated with chronic kidney disease (CKD). Patients with knee osteoar-
thritis (OA) are frequently obese and due to the combined effects of obesity and the chronic use
of non-steroidal anti-inﬂammatory drugs (NSAIDs); they may represent a high risk group for renal
dysfunction. We aimed to detect preclinical renal involvement in obese patients with knee OA.
Patients and methods: Forty patients with knee OA and a body mass index (BMI)P 30 (mean
age 43.5 ± 3.7 years) not on chronic NSAID use and forty age and sex matched non-obese controls
were enrolled in this study. For all subjects anthropometric measures were taken. Laboratory
assessment included fasting blood sugar, serum triglycerides, high density lipoprotein cholesterol
(HDL), serum uric acid, urea, creatinine and microalbuminuria assay. For patients with knee
OA, knee radiographs were done and the disease severity was assessed according to Kellgren–Law-
rence (K–L) scale. Tc-99 m DTPA was used for the measurement of the glomerular ﬁltration rate
(GFR) and the results were classiﬁed into normal and CKD according to Kidney–Dialysis Out-
comes and Quality Initiative stages.
240 H.S. Zayed et al.Results: Among the patients’ group, 26/40 (65%) had CKD compared to 12/40 (30%) subjects
among the controls (P= 0.001). GFR correlated positively with HDL (r= 0.4; P= 0.02) and
inversely with microalbuminuria and the severity of knee OA (r= 0.4; P= 0.02 for each).
Conclusions: Obese patients with knee OA represent a high risk group for renal dysfunction.
 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society for Joint Diseases and
Arthritis.Open access under CC BY-NC-ND license.1. Introduction
Obesity represents one of the most important global public
health issues which because of its rapidly increasing prevalence
and association with a wide range of diseases warrants in-
creased attention by physicians and other health care profes-
sionals [1]. Obesity is deﬁned by a body mass index
(BMI)P 30 kg/m2 [2], while other anthropometric measures
that reﬂect abdominal obesity or central obesity include the
waist circumference (WC), the waist/hip ratio (WHR) and
waist/height ratio (WHtR) [3,4]. Central obesity has been
found to be more related to the metabolic syndrome (MetS)
cluster of cardiovascular risk factors (including central obesity,
hypertension, dyslipidemia and hyperglycemia) than the BMI
[5]. Although anthropometric indicators such as BMI, WC,
WHR, and WHtR have been traditionally used to predict
MetS and associated chronic diseases, there is controversy in
the literature as to which measure of obesity is best related
to cardiovascular risk factors [4].
Obese patients have an increased prevalence of major co-
morbidities including cardiovascular disease, hypertension,
diabetes mellitus and risk factors for chronic kidney disease
(CKD) [6]. In fact, excess body weight has been identiﬁed as
a major risk factor for the development of CKD and end stage
renal disease (ESRD) by itself, independent of blood pressure
levels, and the presence of diabetes signiﬁcantly increases such
a risk [7]. On the other hand, several studies have shown that
even modest impairment in renal function may be an indepen-
dent predictor of cardiovascular morbidity and mortality [8–
10]. Furthermore, microalbuminuria has been found to be a
strong, consistent and independent predictor of all-cause and
cardiovascular mortality and morbidity in individuals with
and without diabetes [11].
Population-based studies of osteoarthritis [OA] have con-
sistently shown that overweight people are at higher risk of
developing knee OA than non-over weight controls [12,13].
Obese women [BMI > 30; yet 6 35] had almost four times risk
of OA as women whose BMI was under 25. For men in the
same weight category; the risk was increased 4.8-fold over nor-
mal weight men [13]. There is growing evidence that osteoar-
thritis is not simply a disease related to aging or mechanical
stress on the joints but rather a ‘‘metabolic disorder’’ in which
various interrelated lipid, metabolic and humoral mediators
contribute to the initiation and progression of the disease pro-
cess [14]. In the Japanese Research on Osteoarthritis against
Disability (ROAD), the odds of OA increased with the pres-
ence of each additional component of the metabolic syndrome
[15]. Similarly, in the Michigan Bone Health and Metabolism
Study, in obese women, the presence of two or more cardio-
metabolic risk factors was associated with more reports of per-
sistent knee pain over the previous 3 years [16]. Patients with
OA frequently use nonsteroidal anti-inﬂammatory drugs[NSAIDs] for pain relief, and since these drugs may adversely
affect renal function especially in the elderly with pre-existing
renal disease, hypertension, heart failure, or those concomi-
tantly treated with anti- hypertensive agents [17], obese pa-
tients with OA due to the combined effects of obesity, MetS
and the side effects of NSAIDs may represent a high risk
group for renal dysfunction. Indeed, besides other risk factors
for cardiovascular disease, OA patients have been found to
have a high prevalence of renal impairment [18].
Although in routine clinical practice serum creatinine is used
to assess renal function; it is inaccurate if used without a correc-
tion factor for sex, age and muscle mass. Besides, isolated re-
duced glomerular ﬁltration rate (GFR) can be present despite
normal serum creatinine which may not be elevated until the
GFR is less than 30–50% of normal [19].’’ The cornerstone for
diagnosing renal disease is GFR which is inﬂuenced by various
factors including structural and/or functional kidney disease
as well as patient’s age, weight, and body surface area. The gold
standard for GFR estimation is inulin clearance, which requires
a steady-state plasma concentration and urine collection but is
too costly and time-consuming. In routine clinical practice,
chromium-51-ethylenediaminetetraacetic acid clearance is a
widely accepted and accurate substitute yet a very expensive
screening tool [10,20]. Subsequently, other isotope clearance
methods have been validated, employing labeled iodothalamate
and diethylenetriamine pentaacetic acid (DTPA) [21].We aimed
to measure the GFR in obese patients with primary knee osteo-
arthritis and normal serum creatinine not on chronic NSAID
use to detect subclinical renal affection in this high risk group
for renal dysfunction and establish relations between obesity,
metabolic risk factors and glomerular function.
2. Patients and methods
The study was a cross-sectional case-control study and was ap-
proved by the local ethics committee of the Cairo University
scientiﬁc review board. Informed consent was obtained from
all subjects according to the Declaration of Helsinki; General
Assembly, October 2008. The study was conducted on 40 pa-
tients with primary knee OA and a BMIP 30 kg/m2 (G1).
They were 35 females and 5 males with a mean age of
(43.5 ± 3.7 years). Knee OA was diagnosed according to the
American College of Rheumatology (ACR) criteria for knee
OA [22]. Forty age and sex matched non-obese healthy sub-
jects were included and served as a control group (G2). Pa-
tients and controls were recruited from the Rheumatology
Department, Cairo University hospitals. Patients with elevated
serum creatinine (>1.2 mg/dl), diabetes (fasting blood su-
garP 126 mg/dl), evidences of urinary tract infection, hyper-
tension (deﬁned as blood pressureP 140/90 mmHg and/or
use of antihypertensive drugs) or other cardiovascular diseases,
abnormal renal sonography or on chronic use of NSAIDs were
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occasionally were not excluded.
All patients and controls were subjected to full history tak-
ing and clinical examination including measurement of blood
pressure (BP), weight, height, WC, WHR, WHtR and articular
examination. WHR was considered increased if P0.9 in men
and P0.85 in women [3] and the cut-point for WHtR was
0.5 for both genders [23].The severity of knee OA on antero-
posterior knee radiographs was assessed according to the Kell-
gren/Lawrence (K–L) grading system [24]. The disease dura-
tion was calculated from the onset of knee pain in months.
BMI was calculated for all subjects. Biochemical analyses
were done after overnight fasting and included fasting blood
sugar (FBS), high density lipoprotein cholesterol (HDL), tri-
glycerides (TG), urea, creatinine and uric acid. The normal
laboratory reference ranges for serum urea, creatinine and uric
acid were 7–21, 0.4–1.2 and 2.5–6.8 mg/dl, respectively. Micro-
albuminuria assay was done by competitive enzyme immuno-
assay, using IMMULITE-2000 apparatus and albumin kits
[25]. Microalbuminuria is deﬁned as a urinary albumin concen-
tration of 20–200 mg/l while urinary albumin concentration
>200 mg/l is considered macroalbuminuria [26]. MetS was
diagnosed when three or more of the following risk factors
were present: WC >88 cm in women and >102 cm in men,
TGsP 150 mg/dl, HDL < 40 mg/dl in males and <50 mg/dl
in females, BPP 130/85 mmHg, FBSP 110 mg/dl according
to the National Cholesterol Education Program-Adult Treat-
ment Panel (NCEP) criteria [27].
All subjects maintained their usual diet, but were recom-
mended to avoid excessive dietary intake of protein or salt
10 days before GFR measurement. Absolute GFR [not the
corrected] was measured using Tc-99 m DTPA; Gates’ method
[28]. Proper hydration was ensured, followed by intravenous
infusion of ﬁve mCi of Tc-99 m DTPA, then serial posterior
dynamic frames were acquired for 6 min. DTPA is taken up
by the kidney through glomerular ﬁltration and is not secreted
or reabsorbed by the renal tubules. Once it reaches the kidney,
about 20% is accumulated, and the remainder ﬂows away; a
value approximating the ﬁltration fraction. Patients’ categori-
zation was performed according to the recommendations of
Kidney–Dialysis Outcomes and Quality Initiative (K/DOQI)
[29] using GFR. Stage I represents patients with normal
GFRP 90 ml/min with kidney damage as manifested byTable 1 Clinical and physical parameters in patients and
controls.
Patients (G1) Patients (G2) P-value
Age (years) 43.5 ± 3.7 44.4 ± 3.9 0.9
Sex distribution –
Females 35 (87.5%) 35 (87.5%)
Males 5 (12.5%) 5 (12.5%)
WC (cm) 116.9 ± 15 77 ± 5.2 0.000
WHR 1 ± 0.1 0.8 ± 0.1 0.000
WHtR 0.7 ± 0.1 0.5 ± 0.02 0.000
BMI 37.28 ± 5.9 23.5 ± 1.3 0.000
SBP (mm Hg) 115.9 ± 13.1 112.4 ± 10.3 0.8
DBP (mm Hg) 74.4 ± 11 71.8 ± 9.3 0.9
G1, group 1; G2, group 2; WC, Waist circumference; WHR, waist-
hip ratio; WHtR, waist-height ratio; BMI, body mass index; SBP,
systolic blood pressure; DBP, diastolic blood pressure. Values are
expressed as mean ± SD or no (%).abnormalities noted on renal pathology, blood, urine or imag-
ing tests while stage II–V represent those with CKD.
All statistical calculations were done using computer pro-
gram SPSS version-15 for Microsoft Windows. Data were sta-
tistically described in terms of mean ± standard deviation
(±SD), median and range, or frequencies (number of cases)
and percentages when appropriate. Comparison of numerical
variables between the study groups was done using Student’s
t test for independent samples. For comparing categorical
data, Chi square (v2) test was performed. Exact test was used
instead when the expected frequency is less than 5. Correlation
between various variables was done using Spearman’s rank
correlation equation. Linear annual reduction in GFR was cal-
culated in knee OA patients. P values less than 0.05 were con-
sidered statistically signiﬁcant.
3. Results
This study included 40 obese patients with primary knee OA
(age range 40–52; mean 43.5 ± 3.7 years) including 35 females
and 5 males, classiﬁed as G1. Thirty patients did not use NSA-
IDs, while 10 others used NSAIDs on intermittent basis one to
three times/week. The means of BMI and disease duration of
G1 were 37.28 ± 5.9 (range; 30–50 kg/m2) and 20.2 ± 14.7
(range; 3–25 months) respectively. According to K–L grading
system for radiographic severity of OA; we found 4 (10%),
20 (50%), 14 (35%) and 2 (5%) belonging to grades 1, 2, 3
and 4 respectively. Thirty-nine (97.5%) OA patients were
found to have MetS. The last patient had abdominal obesity
and a low HDL level but did not fulﬁll the criteria for the diag-
nosis of MetS. Forty age (44.4 ± 3.9 years) and sex (35 fe-
males and 5 males) matched, non-obese subjects served as a
control group with BMI of 23.5 ± 1.3 (range; 19–25 kg/m2)
and were classiﬁed as G2. The different clinical and physical
parameters of both groups are shown in Table 1. BMI, WC,
WHR and WHtR were signiﬁcantly higher in G1 than in G2
(P= 0.000) while there was no statistical difference in systolic
or diastolic blood pressures between both groups.
The laboratory data and GFR are detailed in Table 2. FBS,
uric acid, TG, and microalbuminuria were signiﬁcantly higher
in G1 (P= 0.004, 0.000, 0.000, 0.008, respectively) while HDL
was signiﬁcantly lower (P= 0.000) than in G2. Among G1,Table 2 Laboratory data and glomerular ﬁltration rate of the
study groups.
Patients (G1) Control (G2) P-value
FBS (mg %) 102 ± 12.7 93.7 ± 12 0.004
Creatinine (mg/dl) 0.6 ± 0.1 0.6 ± 0.1 0.9
Urea (mg/dl) 11.4 ± 3.6 12.5 ± 4 0.9
Uric acid (mg/dl) 4.3 ± 0.9 3.5 ± 0.8 0.000
TG (mg/dl) 439.4 ± 190.5 150 ± 31 0.000
HDL (mg/dl) 33.3 ± 7.7 48 ± 0.8 0.000
Microalbuminuria (mg/l) 37.2 ± 4 17 ± 5 0.008
GFR (ml/min) 82.8 ± 17.8 94.2 ± 10.3 0.001
Range (32–120) Range (82–120)
MS (No. %) 39/40 (97.5%) 0 0.000
FBS, fasting blood sugar; TG, Triglycerides; HDL, high density
lipoprotein; GFR, glomerular ﬁltration rate; MS, metabolic syn-
drome. Values are expressed as mean ± SD unless otherwise
speciﬁed.
Table 3 Categorization of patients and controls based on K/
DOQI staging system.
Patients (G1) Control (G2) P-value
Entirely normal 14 (35%) 28 (70%) 0.01
K/DOQI Staging
Stage I 0 0 –
Stage II 22 (55%) 12 (30%) 0.01
Stage III 4 (10%) 0 0.01
Stage IV and V 0 0 –
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none in G2 (P= 0.000). Serum urea and creatinine were not
signiﬁcantly different between both groups, however G1 pa-
tients had signiﬁcantly lower mean GFR in comparison to
G2 (P= 0.001).
Patients’ categorization into normal and chronic kidney
disease (CKD) using GFR is shown in Table 3. 26/40 (65%)
were positive for CKD in G1 compared to 12/40 (30%) in
G2 (P< 0.01). Calculated annual reduction in GFR in G1
was 1.65 ± 0.2 ml/min/1.73 m2/year.
Correlations were done between the different physical, clin-
ical, laboratory and radiological parameters in G1 with GFR.
There was a signiﬁcantly positive correlation with HDL
(P= 0.002) and a signiﬁcantly negative correlation with
microalbuminuria and K–L grade of OA severity (P= 0.003
for both). None of the parameters showed signiﬁcant correla-
tion in the control group (G2). Regarding microalbuminuria,
statistically signiﬁcant positive correlations were found with
disease duration, WHtR, BMI and K–L grade (P= 0.02,
0.03 and 0.03, 0.01, respectively) and a statistically signiﬁcant
negative correlation was found with HDL (P= 0.02) Finally,
K–L grade for OA severity showed statistically signiﬁcant po-
sitive correlation with disease duration, WC, WHtR, BMI
(P= 0.001, 0.005, 0.004, 0.001, respectively, as well as a signif-
icantly negative correlation with HDL (P= 0.02). All correla-
tions are detailed in Table 4.
4. Discussion
This study showed that obese patients with knee OA represent
a high risk group for renal dysfunction. The mean GFR in OA
patients was signiﬁcantly lower compared to the control groupTable 4 Correlations among physical, clinical and laboratory para
Compared Parameter GFR
R P-value
Disease duration 0.3 0.1
WC 0.1 0.6
WHR 0.2 0.1
WHtR 0.2 0.3
BMI 0.1 0.4
FBS 0.1 0.6
TG 0.2 0.2
HDL 0.4 0.02*
Microalbuminuria 0.4 0.03*
K–L grade 0.4 0.03*
G1, group 1; WC, waist circumference; WHR, waist-hip ratio; WHtR, wai
triglycerides; HDL, high density lipoprotein; GFR, Glomerular ﬁltration
* P< 0.05 signiﬁcant correlation.(P= 0.001) with 65% of OA patients having CKD versus
30% of the control group.
Consistent with previous reports on the association of obes-
ity with knee OA [12,13]; in this study, the severity of OA as
assessed by the K–L grade was signiﬁcantly positively corre-
lated with BMI, WC and WHtR. Expectedly, a signiﬁcantly
positive correlation was found between the disease duration
and K–L grade (r 0. 8, P= 0.001).
In a population based study in the United States, MetS was
seen in 59% of the population with OA compared to 23% in
the non OA population. The association between MetS and
OA was strongest in the younger population and diminished
with increasing age; having OA at a mean age of 43.8 years
was associated with a 5.26-fold increased risk of having MetS
[30]. In the present study, 97.5% of patients with knee OA ful-
ﬁlled the criteria of MetS [27] as compared to 0% of the con-
trol group (P= 0.001). The very high prevalence of MetS
among our patients could be explained by their relatively
young age (mean 43.5 ± 3.7 years) and because all patients
were selected to be obese. Regarding individual components
of the MetS [27], the mean FBS in G1 was signiﬁcantly higher
than in controls (P= 0.004), although none of the patients
was in the diabetic range. Also, signiﬁcantly higher triglyceride
levels and signiﬁcantly lower HDL levels were seen in G1
(P= 0.000, each). In our study, a signiﬁcantly negative corre-
lation was found between the K–L grade and the HDL level
(r= 0.4, P= 0.02).
Hyperuricemia is frequently observed in obese subjects due
to the overproduction of uric acid and its impaired renal excre-
tion [31]. Hyperuricemia predicts the development of hyperten-
sion, metabolic syndrome, diabetes, stroke, and cardiovascular
events. Epidemiologic studies have also found that hyperurice-
mia is an independent risk factor for renal dysfunction in the
normal population and in patients with hypertension, diabetes,
and CKD [32]. In the present study, G1 patients had signiﬁ-
cantly higher serum uric acid levels (P= 0.000) than the con-
trol group.
According to the National Health and Nutrition Examina-
tion survey (NHANES III), the MetS is independently associ-
ated with CKD in the general population and in non-diabetic
adults [33,34]. Studies in animals and in humans have shown
that obesity is associated with elevated GFR and increased re-
nal blood ﬂow, i.e. hyperﬁltration [35], however, not all studies
have shown an increase in GFR and renal blood ﬂow in obesemeters in G1with GFR, microalbuminuria and K–L grade.
Microalbuminuria K–L grade
R P-value R P-value
0.5 0.02* 0.8 0.001*
0.3 0.1 0.4 0.005*
0.3 0.08 0.1 0.4
0.4 0.03* 0.4 0.004*
0.5 0.03* 0.5 0.001*
0.1 0.6 0.1 0.5
0.2 0.2 0.2 0.2
0.4 0.02* 0.4 0.02*
– –
0.6 0.01* –
st-height ratio; BMI, body mass index; FBS, fasting blood sugar; TG,
rate; ms, metabolic syndrome; K–L grade, Kellgren/Lawrence grade;
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ducted upon 380,207 individuals, a negative correlation be-
tween BMI and GFR was reported; being most evident in
overweight and obese patients [37]. These controversies could
be explained by the effect of the pattern of obesity on renal
hemodynamics. An elevated BMI with central obesity results
in increased intra-abdominal pressure from visceral fat deposi-
tion which may have several hemodynamic consequences, such
as renal vein compression and may therefore raise renal venous
pressure and diminish renal perfusion [38]. In the present
study, all patients and controls had serum urea and creatinine
within the normal laboratory reference ranges. None of the pa-
tients had hyperﬁltration. Signiﬁcantly lower GFR was found
in G1 (P= 0.001), probably attributed to the very high prev-
alence of MetS among this group. According to the K/DOQI
staging system [29], 55% and 10% of patients of G1 were clas-
siﬁed as stage II and III CKD, respectively, while 30% of the
control group were classiﬁed as class II CKD; P= 0.01. The
GFR was signiﬁcantly negatively correlated with microalbu-
minuria (r= 0.4, P= 0.03), which was expected while no
correlation was found between the GFR and parameters of
obesity among the patients. Obesity has also been associated
with the progression of CKD [39] and by revising the expected
annual reduction [yearly decline] in GFR we found it to be
0.69 mL/min/1.73 m2/year in non-obese subjects using
Tc-99 m DTPA [40]. In our study; the yearly decline in obese
OA subjects was 1.65 ml/min using Tc-99 m DTPA that means
approximately triple (exact ratio 2.75 the yearly GFR decline
in non-obese subjects.
Microalbuminuria reﬂects widespread vascular damage and
generalized vascular endothelial dysfunction. It is related to
the interaction between components of the metabolic syn-
drome, particularly hypertension, insulin resistance and im-
paired glucose tolerance [41]. Indeed, microalbuminuria is
considered as a component of the metabolic syndrome in the
WHO deﬁnition [35]. This association between cardiovascular
damage and low grade albuminuria is independent of renal
function, and in the earliest stages of chronic kidney disease,
low grade albuminuria seems to be a more important determi-
nant than the glomerular ﬁltration rate [42]. In the present
study, G1 patients had signiﬁcantly higher levels of microalbu-
minuria (P= 0.008). Microalbuminuria was signiﬁcantly and
positively correlated with BMI and WHtR ratio (r= 0.5 and
0.4, respectively; P= 0.03 each).
HDL is a risk factor for the development and progression
of kidney dysfunction [37] and there was a signiﬁcantly posi-
tive correlation in G1 between the HDL level and GFR in
OA patients (r= 0.4, P= 0.02) as well as a negative correla-
tion between the HDL level and microalbuminuria (r= 0.4,
P= 0.02).
Due to the high prevalence of both cardiovascular risk fac-
tors and vascular comorbidity in OA it has been hypothesized
that osteoarthritis or at least OA progression may be due to an
atheromatous vascular disease of subchondral bone [43], it has
even been questioned if osteoarthritis could be considered an-
other component of the metabolic syndrome [14]. Recently, a
large population – based study showed independent associa-
tions of atherosclerosis of the carotid arteries with osteoarthri-
tis of the knee and hand joints in women [44]. Since
microalbuminuria is a component of the metabolic syndrome
of cardiovascular risk factors [35], microalbuminuria and
osteoarthritis may represent different aspects of widespreadvascular damage. This might explain the signiﬁcantly negative
correlation that was found in the present study between K–L
stage of OA and GFR (r= 0.4, P= 0.03) and the signiﬁ-
cantly positive correlation between the duration of OA and
K–L grade with the level of microalbuminuria (r= 0.5 and
0.6, P= 0.02 and 0.01, respectively).
At the end, we have to face our limitations as the relatively
small number of involved subjects and not investigating the ef-
fect of food-intake habits [protein versus vegetarian style and
salt intake habits] that were suggested recently to affect GFR
[45]. Our study is preliminary. Further studies with larger num-
bers of subjects including normal weight patients with knee
OA are needed to investigate the association between osteoar-
thritis and renal dysfunction.
In conclusion, middle-aged obese Egyptian patients with
knee OA represent a high risk group for cardiovascular risk
and renal dysfunction. Renal dysfunction is associated with
the degree of obesity, low HDL level and with longer duration
and increased severity of OA. Treating physicians should be
cautious when describing non-steroidal anti-inﬂammatory
drugs for these patients. Maintenance of a healthy life style
to control body weight is strongly recommended.Conﬂict of interest
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